Shots:

• The P-III KEYNOTE-522 study involves assessing of Keytruda + CT vs PBO + CT as neoadjuvant therapy- followed Keytruda vs PBO as adjuvant therapy in 1-174 patients in a ratio (2:1) with TNBC
• The P-III KEYNOTE-522 study resulted in meeting its one of the dual 1EPs i.e- improvement in pCR rates regardless of PD-L1 status- safe and tolerable- no new safety signals were observed
•  Keytruda is an anti-PD-1 therapy- blocking the interaction between PD-1 and its ligands- PD-L1 and PD-L2 and activated T-lymphocytes affecting both tumor and healthy cells- being evaluated in three ongoing studies for TNBC (KEYNOTE-355- KEYNOTE-242 and KEYNOTE-522)

Click here to­ read full press release/ article

Ref: Merck | Image: Merck